August 16, 2023 7:51am

As investors await further clues on the path of interest rates from the US Federal Reserve.

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

News: bluebird bio (BLUE) the U.S. FDA advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel). Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) with a proposed indication for patients ages 12 and older who have a history of vaso-occlusive events (VOEs). The FDA previously accepted the lovo-cel Biologics Licensing Application (BLA) for Priority Review and set a Prescription Drug User Fee Act (PDUFA) goal date of 12/20/23.

Pre-open Indications: x Negative, x Positive and x Sell into Strength

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Never leave an investor uninformed! 

Never leave an investor uninformed!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday

 

Dow futures are UP+0.03% or (+10 point), S&P futures are DOWN -0.01% or (-1 points) and NASDAQ futures are DOWN -0.02% or (-2 points) early in the pre-open – so far

U.S. stock futures fell Wednesday awaiting the release of the minutes from the Federal Reserve’s July meeting minutes,

European markets were mixed as investors assess UK inflation data.

Asia-Pacific markets saw a sell-off on Wednesday, mirroring moves on Wall Street after a decline in U.S. banks.

Economic Data Docket: housing, industrial production and capacity utilization data

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Last night, indexes fell with the Dow closing DOWN -361.24 or -1.02%, the S&P closed DOWN -51.86 or -1.16% while the Nasdaq closed DOWN -157.28 points (-1.14%)

Economic Data Docket: Economists expect report on monthly retail sales to show growth accelerated to 0.4% in July from 0.2% in June.

 

Tuesday’s (8/15) RegMed Investors’ (RMi) closing bell:  contracting sentiment contributes to the brunt of sector selling. CEOs need to step-up and articulate their viability and differentiation to attract investors – speak out and tell investors - why to invest!” … https://www.regmedinvestors.com/articles/13079

 

Ebb and flow:

Q3: August – 2 positive and 9 negative closes

•              July - 1 holiday, 12 positive and 8 negative close

Q2/23 -

•              June -1 Holiday, 8 negative and 11 positive closes

•              May – 10 negative and 12 positive closes

•              April ended - 1 holiday, 8 positive close and 11 negative closes

Q1/23 –-

•              March – ended with 10 positive and 13 negative closes

•              February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

•              January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

I am parsing any indication forecast as the cards shuffled aren’t worth a bet !

 

The BOTTOM LINE:

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all, as I try to keep it simple and short!

It seems news is all about the path of interest rates from the Fed.

There are currently hardly any catalyst, which in turn gives the weak economic forecasts more room to move share pricing.

It “ain’t” been a good August for the cell and gene therapy sector as it suffers 2 positive and 9 negative closes so far.

There's ALSO nothing wrong with standing pat in the short run, holding on to sizable existing exposure.

I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.